Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Alector, Inc. (ALEC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Alector Reports Second Quarter 2023 Financial Results and Provides Business Update Closed screening in the INVOKE-2 Phase 2 trial of AL002 in participants with early Alzheimer’s disease; completing enrollment in Q3 2023, with data readout expected in Q4 2024 Presented update on INVOKE-2 at the Alzheimer’s Association International Conference Anticipate completing enrollment in pivotal INFRONT-3 trial of latozinemab with symptomatic FTD-GRN participants in Q4 2023 based on recent interactions with the FDA and EMA $630.0 million in cash, cash equivalents and investments provide runway through 2025; revenue and expense guidance updated for 2023 Management to host conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT South San Francisco, Calif.,"
05/04/2023 8-K Quarterly results
04/27/2023 8-K Quarterly results
03/29/2023 8-K Quarterly results
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
02/28/2023 8-K Quarterly results
Docs: "Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update On track to complete enrollment in the INVOKE-2 Phase 2 clinical trial of AL002 in patients with early Alzheimer’s disease in Q3 2023, with data readout expected by Q4 2024 Preparing to engage with regulatory authorities in mid-2023 and targeting data readout from the pivotal INFRONT-3 clinical trial for latozinemab in early 2025 pending regulatory feedback Additional data from the INFRONT-2 Phase 2 clinical trial of latozinemab in FTD-C9orf72 expected during the second half of 2023 Company and GSK plan to advance AL101 program in 2023, with the initiation of a PK bridging study to be followed by a global Phase 2 clinical trial in early Alzheimer’s disease $712.9 million in cash, cash equivale..."
11/08/2022 8-K Quarterly results
10/05/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
07/07/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/29/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Role overview: You will be an exempt, salaried employee serving full-time as Chief Medical Officer. You will be responsible for duties that are consistent with this position, in addition to other duties that may be assigned to you by the Company. You will report to Sara Kenkare-Mitra, President and Head of Research and Development. The Company may modify job titles, reporting relationships, salaries and benefits, and other terms and conditions of employment from time to time as it deems necessary and in its sole discretion depending on business needs. 2. Start Date: Your start date will be Monday, May 23, 2021, or a date mutually agreed upon by you and the Company. Commencing employment and your actual start date is contingent upon you first satisfying our reference and post-offer backgrou...",
"Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer South San Francisco, Calif., March 29, 2022 -- Alector, Inc. , a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Romano will lead the company’s global clinical development strategy, including oversight of the clinical development, clinical operations, biometrics and digital science, and medical affairs functions. Dr. Romano will report to Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development of Alector. Dr. Romano’s appointment is effective May 23, 2022. “We are delighted to welcome Gary to our executive leadership team,” said Dr. Kenkare-Mitra. &#x201c..."
02/24/2022 8-K Quarterly results
02/07/2022 8-K Quarterly results
01/03/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Separation Agreement and Release of Claims, by and between Shehnaaz Suliman and Alector, LLC",
"Separation Agreement and Release of Claims, by and between Shehnaaz Suliman and Alector, LLC"
01/03/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "2022 Inducement Equity Incentive Plan and related forms of stock option and restricted stock unit agreements",
"2022 Inducement Equity Incentive Plan and related forms of stock option and restricted stock unit agreements"
12/15/2021 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Alector Reports Third Quarter 2021 Financial Results Initiated Phase 2 Clinical Trial of AL001 for the Treatment of Amyotrophic Lateral Sclerosis Executed a Global Collaboration with GSK to Co-development and Co-commercialize Alector’s Progranulin Franchise Molecules for the Treatment of a Range of Neurodegenerative Diseases South San Francisco, California,"
09/28/2021 8-K Quarterly results
09/08/2021 8-K Quarterly results
09/07/2021 8-K Quarterly results
08/03/2021 8-K Quarterly results
Docs: "Alector Reports Second Quarter 2021 Financial Results Presented twelve-month data from ongoing AL001 open-label Phase 2 study in FTD-GRN at the 2021 Alzheimer’s Association International Conference Announced global collaboration with GSK to co-develop and co-commercialize progranulin-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases"
07/29/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation AL001 Successfully Restored Progranulin to Normal Levels in FTD-GRN Patients Treatment with AL001 Slowed Clinical Progression by 47% Based on the CDR® plus NACC FTLD-SB Scale Relative to GENFI2 Matched Control Cohort Consistent Trends toward Normalization or Stabilization in Multiple Disease Biomarkers Observed with AL001 Treatment Data from Phase 2 Study Presented at Alzheimer’s Association International Conference; Management to Host Webcast to Review Results Today at 1:00 p.m. ET Denver, CO, July 29, 2021 -- Alector, Inc. , a clinical-stage biotechnology company pioneering immuno-neurology, presented..."
07/07/2021 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "For media and investors only Issued: 7:30AM ET, 2 July 2021, London UK Alector and GSK announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases"
06/21/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
03/26/2021 8-K Quarterly results
03/05/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
01/20/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Alector Announces Departure of Chief Business Officer"
11/10/2020 8-K Quarterly results
Docs: "Alector Reports Third Quarter 2020 Financial Results and Provides Corporate Update"
10/06/2020 8-K Quarterly results
08/11/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy